-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-05-28
RLLVF:OTC- (USD)
COMMON STOCK | Pharmaceutical Retailers |
Last Closing
USD 0.006Change
0.00 (0.00)%Market Cap
USD 5.28MVolume
N/AVerdict
Verdict
Values as of: 2025-05-28
COMMON STOCK | Pharmaceutical Retailers |
Last Closing
USD 0.006Change
0.00 (0.00)%Market Cap
USD 5.28MVolume
N/AVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
JDHIY | JD Health International Inc |
N/A |
USD 16.82B |
ALBHF | Alibaba Health Information Tec.. |
N/A |
USD 10.86B |
JDHIF | JD Health International Inc |
N/A |
USD 10.33B |
CLCGY | Clicks Group Ltd |
+1.24 (+2.88%) |
USD 5.14B |
RADLY | Raia Drogasil SA ADR |
-0.19 (-6.48%) |
USD 4.65B |
SHPPF | Shop Apotheke Europe N.V |
N/A |
USD 2.98B |
SAEYY | Shop Apotheke Europe N.V |
N/A |
USD 2.96B |
NOTR | Nowtransit Inc |
N/A |
USD 0.57B |
ZRSEF | Zur Rose Group AG |
N/A |
USD 0.30B |
BLMH | Blum Holdings Inc |
-0.05 (-6.67%) |
USD 0.01B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
VXC:CA | Vanguard FTSE Global All .. | 26.45 % | 0.27 % |
+0.14 (+0.16%) |
CAD 2.27B |
VBAL:CA | Vanguard Balanced Portfol.. | 0.00 % | 0.25 % |
+0.03 (+0.16%) |
CAD 3.43B |
VCNS:CA | Vanguard Conservative ETF.. | 0.00 % | 0.25 % |
+0.05 (+0.16%) |
CAD 0.54B |
VGRO:CA | Vanguard Growth Portfolio | 0.00 % | 0.25 % |
+0.04 (+0.16%) |
CAD 6.59B |
VCIP:CA | Vanguard Conservative Inc.. | 0.00 % | 0.25 % |
+0.05 (+0.16%) |
CAD 0.23B |
VEQT:CA | Vanguard All-Equity ETF P.. | 0.00 % | 0.25 % |
+0.03 (+0.16%) |
CAD 6.50B |
VI:CA | Vanguard FTSE Developed A.. | 0.00 % | 0.23 % |
+0.01 (+0.16%) |
N/A |
VRIF:CA | Vanguard Retirement Incom.. | 0.00 % | 0.00 % |
+0.04 (+0.16%) |
CAD 0.27B |
Market Performance vs. Industry/Classification (Pharmaceutical Retailers) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 12 Months | |||||||
Capital Gain | 5,900.00% | 100% | F | 99% | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 5,900.00% | 100% | F | 99% | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | -80.00% | 67% | D+ | 25% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -80.00% | 67% | D+ | 24% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 415.92% | 92% | A | 93% | A | ||
Dividend Return | 415.92% | 92% | A | 93% | A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 1,608.88% | 12% | F | 7% | C- | ||
Risk Adjusted Return | 25.85% | 80% | B- | 66% | D+ | ||
Market Capitalization | 5.28M | 50% | F | 33% | F |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers median on a price to book value basis.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.